Global Dexamethasone for COVID-19 Market Insights, Forecast to 2028

Dexamethasone for COVID-19 is a corticosteroid hormone drug. Hormones are so-called long-distance chemical messengers. These types of hormones are released from glands found on the kidneys that are known as adrenal glands. The adrenal glands mediate stress response with the production of these corticosteroid messengers. Dexamethasone is a synthetic source of corticosteroid hormones. When taken, Dexamethasone will enter the bloodstream and perform similar regulatory tasks as natural corticosteroids, namely decrease the immune response, and reduce inflammation/swelling/allergic-type reactions. the severe inflammation of vital organs caused by the body’s response to COVID-19 seems to be the leading cause of coronavirus deaths. Dexamethasone can reduce risk of dying in critically ill patients.
Market Analysis and Insights: Global Dexamethasone for COVID-19 Market
Due to the COVID-19 pandemic, the global Dexamethasone for COVID-19 market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 97% Purity accounting for % of the Dexamethasone for COVID-19 global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Dexamethasone for COVID-19 market size is valued at US$ million in 2021, while the US and Europe Dexamethasone for COVID-19 are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Dexamethasone for COVID-19 landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Dexamethasone for COVID-19 include Pfizer, Novartis, Merck & Co., Sanofi Pharmaceuticals, Baxter International, Zydus Cadila, Endo International, Aspen Pharmacare Holdings and Hikma Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Dexamethasone for COVID-19 Scope and Segment
Dexamethasone for COVID-19 market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Dexamethasone for COVID-19 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
97% Purity
99% Purity
Others
Segment by Application
Hospitals
Clinics
Others
By Company
Pfizer
Novartis
Merck & Co.
Sanofi Pharmaceuticals
Baxter International
Zydus Cadila
Endo International
Aspen Pharmacare Holdings
Hikma Pharmaceuticals
Cipla Limited
Wockhardt Limited
Xspire Pharmaceuticals
Fera Pharmaceuticals
Aché Laboratórios
WraSer Pharmaceuticals
Mylan
Bound Tree Medical
Santa Cruz Biotechnology
KingYork
Lingrui Pharmaceutical
North China Pharmaceutical
Shanghai Shyndec Pharmaceutical
Pharscin Pharmaceutical
China Resources Sanjiu Pharmaceutical
Reyphon Pharmaceutical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE